Evidence map›Paper›PMID 33528025›Full record

ArticleTransfusion2021

Reduction of anti-K-mediated hemolytic disease of newborns after the introduction of a matched transfusion policy: A nation-wide policy change evaluation study in the Netherlands.

Jessie S Luken, Claudia C Folman, Michaël V Lukens, Johan H Meekers, Peter C Ligthart, Henk Schonewille, Jaap Jan Zwaginga, Mart P Janssen, C Ellen van der Schoot, Johanna G van der Bom and 1 more

Open access · hybridAbstract readEvaluation Study
In one paragraph

Article in Transfusion, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Alloimmune hemolytic disease of the fetus and newborn: genetics, structure, and function of the commonly involved erythrocyte antigens.Journal of perinatology : official journal of the California Perinatal Association · 2023
    Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jessie S LukenDepartment of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, The Netherlands.ORCID 0000-0001-7300-6794
Claudia C FolmanDepartment of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, The Netherlands.ORCID 0000-0003-1346-4202
Michaël V LukensDepartment of Laboratory Medicine, University Medical Center Groningen (UMCG), Groningen, The Netherlands.
Johan H MeekersDepartment of Laboratory Medicine, University Medical Center Groningen (UMCG), Groningen, The Netherlands.ORCID 0000-0003-1480-7879
Peter C LigthartDepartment of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, The Netherlands.
Henk SchonewilleDepartment of Experimental Immunohematology, Sanquin Research, Amsterdam, The Netherlands.ORCID 0000-0002-4441-5051
Jaap Jan ZwagingaDepartment of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-1228-7769
Mart P JanssenTransfusion Technology Assessment Department, Donor Medicine Research, Sanquin Research, Amsterdam, The Netherlands.ORCID 0000-0002-1682-7817
C Ellen van der SchootDepartment of Experimental Immunohematology, Sanquin Research, Amsterdam, The Netherlands.ORCID 0000-0002-8065-3540
Johanna G van der BomCenter for Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands.ORCID 0000-0001-9095-2475
Masja de HaasDepartment of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, The Netherlands.ORCID 0000-0002-7044-0525
Sanquin · NLLeiden University Medical Center · NLUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDuring pregnancy, maternal red blood cell (RBC) antibodies can lead to life-threatening fetal hemolysis and anemia. Women can become immunized by a pregnancy or an unmatched transfusion. Our aim was to quantify the effect of a nationwide K-matched transfusion policy for women of childbearing age potential to prevent K-immunization in pregnancy. STUDY DESIGN AND

methodsIn this nation-wide policy change evaluation study we determined the occurrence of RBC antibodies before and after introduction of a K-matched transfusion policy and evaluated the cause K alloimmunization 10 years after introduction of this measure. K-matched transfusion for females under 45 years of age is advised in the Dutch transfusion guideline since 2004. We used laboratory data from pregnancies with RBC antibodies identified in the period 1999-2018 obtained as part of a population-based screening program in the Netherlands.

resultsTests of 36 286 pregnancies produced a positive antibody screening result which concerned anti-K in 1550 pregnancies. The occurrence of anti-K decreased from 67.9 to 20.2 per 100 000 pregnancies. The relative risk reduction was 0.70 which largely exceeded the relative risk reduction of 0.27 for antibodies against RBC antigens for which no preventive matching is required. The number of pregnancies at risk for anti-K-mediated disease decreased from 9.7 to 4.2 per 100 000 pregnancies.

conclusionsA K-matched transfusion policy is associated with a major decrease in a number of pregnant women with anti-K and pregnancies at risk for anti-K-mediated disease. A relatively simple measure is now shown to impact prevention of hemolytic disease in the fetus and newborn.

Indexed as

AdultBlood Group IncompatibilityBlood TransfusionErythroblastosis, FetalErythrocytesFemaleHealth Planning GuidelinesHemolysisHumansInfant, NewbornIsoantibodiesKell Blood-Group SystemNetherlandsOdds RatioPolicyPregnancyIsoantibodiesKell Blood-Group System

Identifiers

PMID33528025
PMCPMC7986406
OpenAlexW3127317029

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.